Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Grabner

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|June 9, 2016
Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysisAmy Guo, Michael Grabner, Swetha Rao Palli, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United StatesReema Mody, Qing Huang, Maria Yu, et al.
Tree Physiology|February 8, 2017
Genetic variation, phenotypic stability, and repeatability of drought response in European larch throughout 50 years in a common garden experimentJan-Peter George, Michael Grabner, Sandra Karanitsch-Ackerl, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 10, 2025
Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United StatesReema Mody, Karishma Desai, Chia-Chen Teng, et al.
Diabetes, Obesity & Metabolism|April 4, 2025
Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United StatesReema Mody, Karishma Desai, Chia-Chen Teng, et al.
Advances in Therapy|December 14, 2021
Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care SettingLiya Wang, Yaozhu J Chen, Michael Grabner, et al.
Current Medical Research and Opinion|December 23, 2017
Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatmentReema Mody, Michael Grabner, Maria Yu, et al.
The Science of the Total Environment|January 15, 2019
Intra-specific variation in growth and wood density traits under water-limited conditions: Long-term-, short-term-, and sudden responses of four conifer tree speciesJan-Peter George, Michael Grabner, Filipe Campelo, et al.
Atherosclerosis|June 24, 2014
Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targetsPeter P Toth, Michael Grabner, Rajeshwari S Punekar, et al.
Current Medical Research and Opinion|April 9, 2025
Integration of administrative claims and clinical data to advance real-world evidence generation in oncologyChi Nguyen, Hanke Zheng, Michael Grabner, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Clinicoeconomics and Outcomes Research : CEOR|June 9, 2016
Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysisAmy Guo, Michael Grabner, Swetha Rao Palli, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United StatesReema Mody, Qing Huang, Maria Yu, et al.
Tree Physiology|February 8, 2017
Genetic variation, phenotypic stability, and repeatability of drought response in European larch throughout 50 years in a common garden experimentJan-Peter George, Michael Grabner, Sandra Karanitsch-Ackerl, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 10, 2025
Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United StatesReema Mody, Karishma Desai, Chia-Chen Teng, et al.
Diabetes, Obesity & Metabolism|April 4, 2025
Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United StatesReema Mody, Karishma Desai, Chia-Chen Teng, et al.
Advances in Therapy|December 14, 2021
Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care SettingLiya Wang, Yaozhu J Chen, Michael Grabner, et al.
Current Medical Research and Opinion|December 23, 2017
Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatmentReema Mody, Michael Grabner, Maria Yu, et al.
The Science of the Total Environment|January 15, 2019
Intra-specific variation in growth and wood density traits under water-limited conditions: Long-term-, short-term-, and sudden responses of four conifer tree speciesJan-Peter George, Michael Grabner, Filipe Campelo, et al.
Atherosclerosis|June 24, 2014
Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targetsPeter P Toth, Michael Grabner, Rajeshwari S Punekar, et al.
Current Medical Research and Opinion|April 9, 2025
Integration of administrative claims and clinical data to advance real-world evidence generation in oncologyChi Nguyen, Hanke Zheng, Michael Grabner, et al.
Pageof 9